SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
NVS Analysis & Videos »
NVS: Bull or Bear?
Updated FDA, Clinical Trial Calendars: AZN, MYGN, NVS, PSDV
NVS
|
|
|
+7.65%
in
87 days
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 113 entries through 4/8/09. The FDA Calendar includes the following information: company name, ticker, decision ...
|
A Resurgence in Cell Therapeutics
NVS
|
|
|
-3.12%
in
6 days
(closed on 04/08/09)
Since I profiled Cell Therapeutics (CTIC) two months ago as a cancer biotech that was down, but not out; the stock price has more than quadrupled from 8 cents to 36 cents during intraday trading today. CTIC continues to reduce operating expenses and sold its remaining stake in a joint venture to market cancer drug Zevalin to Spectrum Pharma (SPPI) for $16.5M last month (in addition to receiving $15M last December from SPPI for the initial 50% stake). <> CTIC reduced operating expenses in 2008 by 33% and prov...
|
Updated Clinical Trial and FDA Decision Calendars
NVS
|
|
|
+4.88%
in
18 days
(closed on 04/02/09)
<> <> Below is a summary of updates to the www.BioMedReports.com database of 242 entries included in the FDA and Clinical Trial Calendars. The two web links below are for the FDA calendar home page and a recent article highlighting 14 extreme trades of companies with market caps below $200M with pending FDA decisions.
http://biomedreports <wbr> </wbr> .com/fda-calendar.ht <wbr> </wbr> ml
http://biomedreports <wbr> </wbr> .com/articles/most-p <wbr> </wbr> opular/627-trading-f <wbr> </wbr> da-decisions-14-extr <wbr> </wbr> eme-trades.html
The FDA Calenda...
|
Momenta Pharma's Three-Part Strategy
NVS
|
|
|
+3.59%
in
9 days
(closed on 03/15/09)
Momenta Pharma (MNTA) is pursuing a three-part business model which includes complex generic equivalents in partnership with the Sandoz division of Novartis (NVS), proprietary compounds, and follow-on- biologics (FOB). <> Momenta is partnered with Sandoz to develop a generic equivalent (M-Enoxaparin) of the multi-billion dollar injectable blood thinner Lovenox ($3.9B in worldwide sales for 2008). While MNTA + NVS were not the first to file for a generic version of Lovenox, the 180-day exclusivity period awarded to the first-to-file company is set to expire on 4/1/09 for Amphasta...
|
ETFI Global Healthcare Sector PerformIdex
NVS
|
|
|
-28.44%
in
111 days
(closed on 03/06/09)
<> 
The accompanying table presents the top five rated companies with market caps of at least $250 million (USD) from each of the nine new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 400 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 45 top rated companies ranging from small-caps to mega-caps from the following underlying healthcare indexes:
1.) ETFI Global Hospitals – Fresenius Medical (FMS)
2.) <> ETFI New Drug Regulatory Catalys...
|
Teva Beats on Profits: A Biogeneric Boon in '09?
NVS
|
|
|
+1.46%
in
8 days
(closed on 11/14/08)
<> 
<> Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than dou...
|
My 60 Defensive Growth Stock Picks at Inner8.com
NVS
|
|
|
+3.66%
in
12 days
(closed on 11/06/08)
<> 
<> The accompanying table presents my 60 defensive growth stock picks at the recently launched online investing site Inner8.com , which I wrote about yesterday. My picks are focused on healthcare and consumer staples, along with some cash rich tech companies such as Microsoft (MSFT). My picks include companies across the entire spectrum of market cap and risk in the biotech industry, ranging from top performers such as Amgen (AMGN) and Celgene (CELG) to small and micro-cap picks such as Discovery Labs (DSCO), ...
|
Expanding Defensive Growth Index into Europe
NVS
|
|
|
-4.37%
in
2 days
(closed on 10/25/08)
<> 
<> The accompanying table presents an updated version of the ETFI Highly Defensive PerformIdex, which is expanded to 40 companies with market caps of at least $10B from the industry groups listed below. This defensive growth index is heavily weighted in consumer staples and healthcare and is now structured to include companies based in Europe, in addition to the United States and Canada.
Compared to the previous version, this index has a lower beta and higher average market cap and adds European companie...
|
A Waiting Game for Momenta Pharma
NVS
|
|
|
-10.66%
in
27 days
(closed on 10/23/08)
<> 
According to a SEC 8-K filing today, an amendment has been submitted to the FDA for Momenta Pharma's (MNTA) Enoxaparin Sodium Injection Abbreviated New Drug Application [ANDA] by its partner, Sandoz, which is the generic drug operating division of Novartis (NVS). Momenta believes the amendment represents a complete response to the agency's concerns over the potential for immune-mediated reactions to the product, which is intended to be a generic equivalent of the injectable blood thinner Lovenox.
Momenta Pharma represe...
|
Novartis: An ex-US Proxy for Global Healthcare
NVS
|
|
|
-6.69%
in
62 days
(closed on 09/26/08)
<> In mid-July, Novartis (NVS) reported better-than-expected financial results for Q208 due to sales growth of 14% (which included a 9% forex benefit thanks to a weak US Dollar), resulting in an EPS of $0.98 for the quarter. Pharmaceutical sales were driven by strong demand for the blood pressure drug Diovan, which faces generic competition in 2012, and cancer drugs such as Gleevac, Zometa, and Femara. Novartis is expected to file for regulatory approval of cancer drug Afinitor by the end of this year. As illustrated in the accompanying five-year chart, Novartis has outperformed bo...
|
Bullish on NVS ...
NVS
|
|
|
-29.40%
in
356 days
Analysts' Recommendation: Buy 30 Days Ago: Buy Analysts' Target: $49 Analysts' Targets HSBC Securities $49 Add Thursday, June 12, 2008 BusinessWeek Rankings Best Global Brands Best Global Brands 2006 #43 2005 #43 Novartis AG provides healthcare solutions that address the needs of patients and societies worldwide. Its Pharmaceuticals division researches, develops, manufactures, distributes, and sells pharmaceuticals in therapeutic areas, including cardiovascular and metabolism; oncology and hematology; neuroscience; respiratory; infectious diseases, tra...
|
Novartis (NVS): 'Best pipeline in the business'
NVS
|
|
|
-29.00%
in
365 days
 "The pipelines of most Big Pharmas are bone dry; last year, the FDA approved the lowest number of new drugs (19) since 1983," notes Louis Basenese, contributing editor to the industry-leading The Oxford Club.
"But opportunity always lurks in the wreckage, and one Big Pharma, in particular, is being unfairly punished." Here's his bullish outlook on Novartis (NYSE: NVS), which he calls the "only Big Pharma worth owning." <>"Unlike others in the sector, Novartis doesn't suffer from an empty pipeline. It's launched more drugs globally than any other firm in the past seven years. It has more than 1...
|
Good growth in Drugs
NVS
|
|
|
-31.71%
in
541 days
In my opinion, global large-cap pharmacueticial stocks, including Pfizer , Novartis , Astrazenca , GlaxoSmithKline , Wyeth and Eli Lilly are currently substantially undervalued. These companies are currently paying out huge dividends and trading at sensible P/Es. Unlike their small-cap high-risk research counterparts, these blue-chip stocks represent strong, yet low risk growth. Why risk your money on an obscure new cure for bird-flu, from a dodgy one-man company, when you don't have to?
While sales of their products may be slowing in the OECD developed worl...
|
Bullish on NVS ...
NVS
|
|
|
-27.35%
in
1135 days
Buy Report: Novartis AG ADR (NYSE: NVS) prepared 20060417
Key Stats:
Last Close: $55.81
Market Cap $Mil: 130,368
Sales $Mil: 35,526
About Novartis:
- Latin for “New Arts,� Novartis is a Switzerland-based manufacturer of pharmaceutical, health-care, and vision products. The firm was formed in 1996 by the merger of Ciba-Geigy and Sandoz. Areas of specialty in branded drugs include oncology and cardiovascular products. Consumer health-care brands include such familiar names as Ex-Lax, Maalox, Lamisil, and Gerber. Its Ceiba-Geigy division makes disposable contact lenses as well as ...
|
People Bullish on NVS
People Bearish on NVS
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
About Novartis AG
- Answers.com
I am the Global Editor at 
